Louis J. DeGennaro, Ph.D., was named president and chief executive officer of The Leukemia & Lymphoma Society (LLS) in September 2014 and now leads theoperations of this $300 million cancer patient advocacy agency with headquartersin White Plains, New York.
A critical member of the LLS executive leadership team, he joined LLS in 2005 andwas named chief mission officer in 2009, with responsibility for leadership of LLS’smission functions of research, patient access, education, public policy andadvocacy. Dr. DeGennaro is recognized as the key architect of LLS’s cures andaccess agenda to help save lives of blood cancer patients as well as the LLSTherapy Acceleration Program® - a venture philanthropy endeavor that definedthe role of nonprofit organizations in supporting drug discovery and developmentwith the biotechnology industry.
Dr. DeGennaro has more than 25 years of research, drug development andexecutive management experience in academic and private sector settings. Hereceived his Ph.D. in biochemistry from the University of California at SanFrancisco and did his post-doctoral research at the Yale University School ofMedicine. His previous academic appointments include research group leader,Max Planck Institute in Munich, Germany and associate professor of neurologyand cell biology, University of Massachusetts Medical School. Dr. DeGennaro's private-sector positions include senior director of molecular genetics at WyethPharmaceuticals, Princeton, NJ, and executive vice president for research anddevelopment, SynX Pharma, Inc. in Toronto, Canada.